On December 3, 2014, the Federal Circuit issued a decision in Par Pharmaceutical, Inc. and Alkermes Pharma Ireland Limited v. TWI Pharmaceuticals, Inc., agreeing with the district court’s analysis and conclusions on motivation to combine, reasonable expectation of success, and objective indicia of nonobviousness but vacating and remanding for further analysis on the issue of inherency.
Download the attached PDF for our analysis on the decision and its impact on inherent obviousness.
Download
PDF
Stay in the Know
Receive insights from the most respected practitioners of IP law, straight to your inbox.
Subscribe for Updates